LOGIN  |  REGISTER
Terns Pharmaceuticals
Chimerix

QuidelOrtho - The Power of Prevention: Detecting Diabetes Before It Strikes

November 20, 2025 | Last Trade: US$27.50 0.00 0.00

SAN DIEGO, Nov. 20, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 53 of its Science Bytes podcast, featuring Qian Ding, MD, PhD, Senior Medical Affairs Manager, QuidelOrtho, an expert in clinical and laboratory medicine with deep experience in healthcare information systems and data analytics.

In the episode titled "Don't Wait for the Wake-Up Call," Dr. Ding explains why early detection of diabetes is a clinical and economic priority. With diabetes affecting millions of people worldwide – many undiagnosed until complications arise – early testing offers a critical opportunity to shift care from reactive to proactive. Dr. Ding shares how modern laboratory platforms and emerging biomarkers are helping clinicians intervene sooner, personalize care and prevent long-term harm.

Key insights include:

  • Early action saves lives: Detecting diabetes before complications occur changes the patient's health trajectory.
  • Beyond glucose: Emerging biomarkers like C-peptide, pro-insulin and adiponectin offer a more complete metabolic picture.
  • Smarter labs, faster answers: Automation-ready platforms deliver reliable results quickly, supporting timely clinical decisions.
  • Economic impact: Early testing reduces costly interventions and aligns with value-based care models.
  • Equity in care: Tailored testing strategies ensure accurate diagnosis across diverse populations.

This episode underscores how collaboration between labs and clinicians can help close the loop between diagnostics and care – empowering better outcomes and healthier futures.

The QuidelOrtho Science Bytes podcast is available on major streaming platforms and at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.

About QuidelOrtho Corporation

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to lab, clinic to hospital. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.

Episode 53: QuidelOrtho Science Bytes

Qian Ding, MD, PhD, Senior Medical Affairs Manager, QuidelOrtho

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page